Published in Women's Health Weekly, June 3rd, 2004
Solifenacin appears to be the first antimuscarinic agent to report consistent and statistically significant reductions in the three main symptoms of OAB across multiple trials in both men and women. OAB is a condition that affects approximately 17% of women 40 years of age or older.
The data showed that 63% of women...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.